Dr. Martens (LON:DOCS - Get Free Report) announced its earnings results on Thursday. The company reported GBX 2.40 ($0.03) earnings per share for the quarter, Digital Look Earnings reports. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%.
Dr. Martens Stock Up 8.7%
Shares of LON:DOCS traded up GBX 6.55 ($0.09) during trading on Friday, hitting GBX 81.95 ($1.11). 5,848,008 shares of the company's stock traded hands, compared to its average volume of 2,287,045. Dr. Martens has a 52 week low of GBX 43.02 ($0.58) and a 52 week high of GBX 88 ($1.19). The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The company has a market cap of £795.54 million, a price-to-earnings ratio of 11.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a 50-day moving average price of GBX 55.34 and a 200-day moving average price of GBX 62.91.
Dr. Martens Cuts Dividend
The firm also recently disclosed a dividend, which was paid on Tuesday, April 8th. Stockholders of record on Thursday, March 6th were issued a dividend of GBX 0.85 ($0.01) per share. This represents a dividend yield of 1.47%. The ex-dividend date of this dividend was Thursday, March 6th. Dr. Martens's dividend payout ratio (DPR) is presently 42.53%.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada decreased their price target on Dr. Martens from GBX 7,000 ($94.75) to GBX 6,000 ($81.21) and set a "sector perform" rating on the stock in a report on Monday, May 19th.
Check Out Our Latest Research Report on Dr. Martens
Insider Activity
In other news, insider Giles Wilson bought 32,640 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were acquired at an average price of GBX 54 ($0.73) per share, with a total value of £17,625.60 ($23,857.07). Insiders have acquired 33,206 shares of company stock worth $1,792,771 in the last 90 days. Corporate insiders own 4.36% of the company's stock.
About Dr. Martens
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Read More
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.